Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US FDA Getting More Money Up Front Under Cures Bill Revisions

Executive Summary

Additional funding would arrive beginning in FY 2017 as House pushes bill to Senate.

You may also be interested in...



FY 2021 Appropriations Provides FDA Healthy Boost – Plus More COVID-19 Funds

Budget authority increase for medical product safety is coupled with additional funds for coronavirus countermeasure development and advanced manufacturing.

House Would Slow US FDA Budget Authority Increases In FY 2021

After two years of significant growth in non-user fee funds, House appropriators offer FDA a more modest increase for FY 2021.

US FDA’s Human Drugs Program Suffers In Adjustment Of Agency Priorities

President Trump's budget request would boost compounding and vaccines by $5m, but human drugs program would lose $4.8m in training funds.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

PS119597

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel